Pivotal Scientific advises EastCoast Bio on its sale to Medix Biochemica
Jun 5, 2020
Jun 5, 2020
Pivotal Scientific is delighted to announce its assistance in the sale of US based biotech firm EastCoast Bio to the Finnish leading supplier of IVD products, Medix Biochemica. The acquisition will broaden Medix Biochemica’s product portfolio for the IVD manufacturing industry worldwide and expand their US presence, whilst EastCoast Bio will benefit from Medix Biochemica’s strong commercial presence in Europe and China.
Pivotal Scientific Limited supported EastCoast Bio throughout the entire process including strategy for forward planning, all M&A documentation and agency management. Our expert knowledge of the global biotech landscape helped us prepare them for a seamless integration offering competitive advantages for both companies and ensuring sustainable value.
“PSL really helped us get ready for sale and managed the process on an end to end basis which allowed my team and I to keep doing what we do best which is serving customers”
Clark Macdermith, EastCoast Bio
“We have been working with EastCoast Bio for nearly two years, originally supporting their planning for continued growth and then in 2019 we started to promote the company for sale. EastCoast Bio has been very successful and delivered sustained growth so the opportunity to come together with Medix Biochemica is beneficial for both companies and customers, especially with such an impressive and comprehensive product range now available”
Tim Bernard, CEO, Pivotal Scientific Limited
If you are looking to buy or sell a company, contact us to find out how we can guide you through the process.